Blog of Signaling Pathways

Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

24 views | Oct 18 2022

Katharina Otte et al. concluded that monotherapy with Eltanexor effectively induced apoptosis in GBM cells and could be combined with current adjuvant therapies to provide a more effective therapy of GBM. [Read the Full Post]

Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis

26 views | Oct 17 2022

Lu Yin et al. found that EGR1 was a new substrate of the GSK3β-FBXW7 axis, and the FBXW7-EGR1 axis coordinately regulated growth of cancer cells. [Read the Full Post]

UC-MSCs promote frozen-thawed ovaries angiogenesis via activation of the Wnt/β-catenin pathway in vitro ovarian culture system

58 views | Oct 16 2022

Wenjuan Xu et al. showed the beneficial effects of UC-MSCs on thawed ovaries and explored a potential mechanism inducing angiogenesis. [Read the Full Post]

Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma

48 views | Oct 16 2022

Janki M Desai et al. found that SBI-0206965 had adequate brain permeability but low relative oral bioavailability which might be due to rapid hepatic metabolism. [Read the Full Post]

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis

34 views | Oct 16 2022

Ze Mi et al. thought that PD-L1 inhibitors plus CTLA-4 inhibitors showed better safety in treatment-related adverse events than PD-1 inhibitors plus CTLA-4 inhibitors. [Read the Full Post]

Luteinizing Hormone Receptor Promotes Angiogenesis In Ovarian Endothelial Cells of Macaca fascicularis and Homo sapiens

41 views | Oct 15 2022

Merete Lund et al. found that the LH surge may directly activate ovarian endothelial cells to stimulate angiogenesis of the ovulatory follicle. [Read the Full Post]

Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis

0 views | Oct 14 2022

Thibaut Burg et al. suggested that HDAC inhibition was a potential new therapeutic strategy to modulate lipid metabolism defects in ALS and potentially other neurodegenerative diseases. [Read the Full Post]

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

50 views | Oct 14 2022

Toni Choueiri et al thought that dual mTORC1/2 inhibition might not be an effective therapeutic approach for patients. [Read the Full Post]

Vascular Disruptive Hydrogel Platform for Enhanced Chemotherapy and Anti-Angiogenesis through Alleviation of Immune Surveillance

37 views | Oct 13 2022

Fasheng Li et al. provided a new treatment strategy through the mediation of the tumor immune microenvironment by vascular disruption to fulfill enhanced chemotherapy and immunotherapy. [Read the Full Post]

Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver

24 views | Oct 13 2022

Wenshu Tang et al. found mTORC1/SREBP2/cholesterol-mediated NKT dysfunction in the tumor-promoting NAFLD liver microenvironment, providing intervention strategies that invigorating NKT cells to control HCC in the obesity epidemic. [Read the Full Post]

The Efficacy of Fosbretabulin Disodium Combined with Radiofrequency Ablation in Lung Cancer

20 views | Oct 12 2022

Jieli Kou et al. found that FBTD promoted the antitumor effects of RFA in lung tumor-bearing mice in the study. [Read the Full Post]

Design, synthesis and biological evaluation of conformationnally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA)

22 views | Oct 12 2022

Vassili Prudhomme et al. found that indole 4j exhibited good potency against HUVEC and HIG-82 cell lines, as well as a good ability to inhibit tubulin assembly. [Read the Full Post]

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

66 views | Oct 11 2022

Panagiotis A Konstantinopoulos et al. discovered that there was no obvious correlation with genomic alterations in responders vs non-responders, emphasizing the need for alternative biomarker approaches for responder identification. [Read the Full Post]

ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells

29 views | Oct 10 2022

Estefanía García-Guerrero et al. found that ATRA treatment lead to enhanced BCMA expression on MM cells and consecutively, enhanced reactivity of BCMA-CAR T-cells. [Read the Full Post]

Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis in vitro and represses tumour growth in an in vivo xenograft model

22 views | Oct 10 2022

Yoshihito Morimoto et al. suggested that the simultaneous inhibition of Chk1 and Bcl-xL might be an effective treatment for pancreatic cancer. [Read the Full Post]

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

97 views | Oct 09 2022

Pia Roering et al. found that Wee1 inhibitor adavosertib affected several critical functions related to proliferation, cell cycle and division, apoptosis, and invasion. [Read the Full Post]

Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice

64 views | Oct 09 2022

Adrian L Oblak et al. demonstrated the rigorous translational approaches of the MODEL-AD PTC for interrogating potential therapeutics and provided insight into the limitations of verubecestat as a prophylactic intervention for early-stage AD. [Read the Full Post]

Exploratory analyses of clinical trial data used for health technology assessments: a retrospective evaluation

77 views | Oct 08 2022

Björn J Oddens et al. found that decisions about benefits of medical products should therefore not rely on exploratory analyses of clinical trial data but rather on prospective clinical studies and careful synthesis of all available evidence based on prespecified criteria. [Read the Full Post]

BDNF and its signaling in cancer

103 views | Oct 07 2022

Mohammad Malekan et al. found that the aberrant signaling of BDNF was implicated in various cancers. [Read the Full Post]

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability

89 views | Oct 07 2022

Wenlong Li et al. found that systemic exposure of repotrectinib was substantially limited by CYP3A activity. [Read the Full Post]